Suppr超能文献

ADCS预防工具项目:药物经济学:评估健康老年人中与健康相关的资源使用情况。

ADCS Prevention Instrument Project: pharmacoeconomics: assessing health-related resource use among healthy elderly.

作者信息

Sano Mary, Zhu Carolyn W, Whitehouse Peter J, Edland Steven, Jin Shelia, Ernstrom Karin, Thomas Ronald G, Thal Leon J, Ferris Steven H

机构信息

Mount Sinai School of Medicine, James J Peters VAMC, Bronx, NY 10468, USA.

出版信息

Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4 Suppl 3):S191-202. doi: 10.1097/01.wad.0000213875.63171.87.

Abstract

BACKGROUND

The Prevention Instrument project of the Alzheimer's Disease Cooperative Study (ADCS) seeks to develop instruments to assess treatment efficacy including potential economic benefit. The Resource Use Inventory (RUI) is an instrument that has been used to capture resource utilization and costs in populations with Alzheimer disease (AD). However, resource utilization and costs for healthy, cognitively intact elderly as they begin to demonstrate cognitive deterioration are not well understood. In addition, the loss that relates to the subjects' own time as they transition through cognitive impairment is not well documented.

OBJECTIVES

To evaluate the utility of the RUI in a sample of cognitively intact elderly individuals living in the community and enrolled in AD prevention trials.

METHODS

The RUI was administered to 644 subjects and their study partners either at home or in the clinic. For half of each sample, 3-month retesting was carried out. The RUI consisted of 9 questions. The first part of the RUI captured subjects' use of direct medical care (eg, hospitalizations) and nonmedical care (eg, home health aides). The second part of the RUI captured the time caregivers spend providing care to the subjects. The third part of the RUI captured subjects' participation in volunteer work and employment. The assessment interval for each question was the past 3 months.

RESULTS

The percentage of RUI forms returned incomplete or inaccurate for both in-clinic and at-home groups was extremely low. There were no differences in utilization rates between in-clinic and at-home group for all items in the RUI. Except for use of outpatient procedures, tests, or treatments, there were no differences in utilization rates between subjects who filled out the RUI with the help of their study partners or by themselves. Items in the RUI were sensitive to subjects' cognitive and functional status and demographic characteristics.

CONCLUSIONS

Home-based completion of the RUI by participants in an AD prevention study is feasible, and seems to provide data that are reliable and valid. The instrument will be useful for tracking resource and time use through transition from healthy to cognitive impairment.

摘要

背景

阿尔茨海默病协作研究(ADCS)的预防工具项目旨在开发评估治疗效果(包括潜在经济效益)的工具。资源使用清单(RUI)是一种用于记录阿尔茨海默病(AD)患者群体资源利用情况和成本的工具。然而,对于健康的、认知功能完好的老年人在开始出现认知衰退时的资源利用情况和成本,我们了解得并不充分。此外,关于受试者在经历认知障碍过程中自身时间的损失,也缺乏充分的记录。

目的

评估RUI在居住在社区且参与AD预防试验的认知功能完好的老年人样本中的效用。

方法

对644名受试者及其研究伙伴在家中或诊所进行RUI问卷调查。每个样本的一半进行为期3个月的重新测试。RUI由9个问题组成。RUI的第一部分记录受试者对直接医疗护理(如住院治疗)和非医疗护理(如家庭健康护理员)的使用情况。RUI的第二部分记录护理人员为受试者提供护理所花费的时间。RUI的第三部分记录受试者参与志愿工作和就业的情况。每个问题的评估时间段为过去3个月。

结果

诊所组和家庭组返回的RUI表格不完整或不准确的比例极低。RUI中所有项目的诊所组和家庭组利用率没有差异。除了门诊手术、检查或治疗的使用情况外,在研究伙伴帮助下填写RUI的受试者和自行填写RUI的受试者之间的利用率没有差异。RUI中的项目对受试者的认知和功能状态以及人口统计学特征敏感。

结论

AD预防研究的参与者在家中完成RUI问卷调查是可行的,且似乎能提供可靠有效的数据。该工具对于跟踪从健康到认知障碍转变过程中的资源和时间使用情况将很有用。

相似文献

1
ADCS Prevention Instrument Project: pharmacoeconomics: assessing health-related resource use among healthy elderly.
Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4 Suppl 3):S191-202. doi: 10.1097/01.wad.0000213875.63171.87.
2
ADCS Prevention Instrument Project: overview and initial results.
Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4 Suppl 3):S109-23. doi: 10.1097/01.wad.0000213870.40300.21.
3
ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions.
Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4 Suppl 3):S124-38. doi: 10.1097/01.wad.0000213878.47924.44.
4
ADCS Prevention Instrument Project: the Mail-In Cognitive Function Screening Instrument (MCFSI).
Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4 Suppl 3):S170-8. doi: 10.1097/01.wad.0000213879.55547.57.
6
ADCS Prevention Instrument Project: quality of life assessment (QOL).
Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4 Suppl 3):S179-90. doi: 10.1097/01.wad.0000213874.25053.e5.
7
ADCS Prevention Instrument Project: behavioral measures in primary prevention trials.
Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4 Suppl 3):S147-51. doi: 10.1097/01.wad.0000213872.17429.0f.
9
Costs of care in a mild-to-moderate Alzheimer clinical trial sample: key resources and their determinants.
Alzheimers Dement. 2011 Jul;7(4):466-73. doi: 10.1016/j.jalz.2010.06.002.

引用本文的文献

1
Meaningful benefit of disease-modifying treatment: Evaluating changes in health-related resource use.
Alzheimers Dement (N Y). 2024 Jul 31;10(3):e12455. doi: 10.1002/trc2.12455. eCollection 2024 Jul-Sep.
4
Major Cost Drivers in Assessing the Economic Burden of Alzheimer's Disease: A Structured, Rapid Review.
J Prev Alzheimers Dis. 2021;8(3):362-370. doi: 10.14283/jpad.2021.17.
8
Analysis of postdischarge costs following emergent general surgery in elderly patients.
Can J Surg. 2018 Feb;61(1):19-27. doi: 10.1503/cjs.002617. Epub 2017 Dec 1.
9
The social and economic burden of frontotemporal degeneration.
Neurology. 2017 Nov 14;89(20):2049-2056. doi: 10.1212/WNL.0000000000004614. Epub 2017 Oct 4.

本文引用的文献

1
ADCS Prevention Instrument Project: overview and initial results.
Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4 Suppl 3):S109-23. doi: 10.1097/01.wad.0000213870.40300.21.
2
Prevalence, resource utilization and costs of vascular dementia compared to Alzheimer's dementia in a population setting.
Dement Geriatr Cogn Disord. 2005;19(5-6):305-15. doi: 10.1159/000084556. Epub 2005 Mar 22.
3
Variation in cost of informal caregiving and formal-service use for people with Alzheimer's disease.
Am J Alzheimers Dis Other Demen. 2004 Sep-Oct;19(5):299-308. doi: 10.1177/153331750401900507.
4
Impact of donepezil treatment for Alzheimer's disease on caregiver time.
Curr Med Res Opin. 2004 Aug;20(8):1221-5. doi: 10.1185/030079902125004349.
5
Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.
Lancet. 2004 Jun 26;363(9427):2105-15. doi: 10.1016/S0140-6736(04)16499-4.
6
The effects of galantamine treatment on caregiver time in Alzheimer's disease.
Int J Geriatr Psychiatry. 2003 Oct;18(10):942-50. doi: 10.1002/gps.1000.
8
Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease.
Pharmacoeconomics. 2003;21(5):327-40. doi: 10.2165/00019053-200321050-00004.
10
Primary care expenditures before the onset of Alzheimer's disease.
Neurology. 2002 Aug 27;59(4):573-8. doi: 10.1212/wnl.59.4.573.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验